Keyword Index
Browse for an article via relevant keywords across our entire electronic archive
Search results for: S
Results 1 - 10 of 551 shown below
-
The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells
doi:10.1038/sj.bjc.6690708
-
Butyrate augments interferon-
-induced S phase accumulation and persistent tyrosine phosphorylation of cdc2 in K562 cellsdoi:10.1038/sj.bjc.6690163
-
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
doi:10.1038/sj.bjc.6690801
-
Plasma concentrations of 5-fluorouracil and F-
-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracildoi:10.1038/sj.bjc.6601224
-
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
doi:10.1038/sj.bjc.6601413
-
Phase II study of S-1 in patients with advanced biliary tract cancer
advance online publication, 2004-10-26 00:00:00.000;
doi:10.1038/sj.bjc.6602208
-
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
advance online publication, 2005-06-07 00:00:00.000;
doi:10.1038/sj.bjc.6602644
-
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer
advance online publication, 2005-09-27 00:00:00.000;
doi:10.1038/sj.bjc.6602804
-
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
advance online publication, 2006-03-28 00:00:00.000;
doi:10.1038/sj.bjc.6603072
-
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
advance online publication, 2006-05-23 00:00:00.000;
doi:10.1038/sj.bjc.6603168
-
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
doi:10.1038/sj.bjc.6603196
-
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
advance online publication, 2007-01-09 00:00:00.000;
doi:10.1038/sj.bjc.6603546
-
Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer
advance online publication, 2007-04-17 00:00:00.000;
doi:10.1038/sj.bjc.6603735
-
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
advance online publication, 2007-05-29 00:00:00.000;
doi:10.1038/sj.bjc.6603788
-
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
advance online publication, 2007-06-05 00:00:00.000;
doi:10.1038/sj.bjc.6603831
-
A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
advance online publication, 2007-07-24 00:00:00.000;
doi:10.1038/sj.bjc.6603902
-
Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
advance online publication, 2007-09-11 00:00:00.000;
doi:10.1038/sj.bjc.6603957
-
Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
advance online publication, 2008-03-04 00:00:00.000;
doi:10.1038/sj.bjc.6604271
-
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
advance online publication, 2008-03-25 00:00:00.000;
doi:10.1038/sj.bjc.6604312
-
The role of S-1 in the treatment of gastric cancer
advance online publication, 2008-03-25 00:00:00.000;
doi:10.1038/sj.bjc.6604332
-
Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
doi:10.1054/bjoc.2000.1236
-
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
doi:10.1054/bjoc.2001.2031
-
Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function
doi:10.1038/sj.bjc.6690827
-
Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
doi:10.1038/sj.bjc.6690173
-
Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma
doi:10.1038/sj.bjc.6690151
-
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells
doi:10.1038/sj.bjc.6600722
-
Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia
advance online publication, 2006-07-11 00:00:00.000;
doi:10.1038/sj.bjc.6603262
-
Prognostic implications of various models for calculation of S-phase fraction in 259 patients with soft tissue sarcoma
doi:10.1038/sj.bjc.6690193
-
Prognostic value of DNA flow cytometry in stomach cancer: a 5-year prospective study
doi:10.1038/sj.bjc.6690275
-
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
doi:10.1038/sj.bjc.6690373
-
Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts
doi:10.1054/bjoc.2000.1373
-
Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma
advance online publication, 2007-06-19 00:00:00.000;
doi:10.1038/sj.bjc.6603852